Foundation Medicine, Inc.

Ucl Business Plc

Genentech, Inc.

Vanderbilt University

Garrett Michael Frampton

Roman Yelensky

Philip James Stephens

Matthew J Hawryluk

Timothy Robert Fenton

Chris Hendrik Boshoff

Matthias Alexander Lechner

Vincent A Miller

James Xin Sun

David Fabrizio

Jeffrey S Ross

Doron Lipson

Priti Hegde

Gary Palmer

Maureen T Cronin

Sanjeev Mariathasan

Richard Bourgon

Gregg Fine

Marcin Kowanetz

David Shames

Douglas B Johnson

Wei Zou

Jeffrey Alan Sosman

Christine Marie Lovly

Philip J Stephens

Zachary R Chalmers

Caitlin F Connelly

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

Therapeutic and diagnostic methods for cancer

Novel mutant ESR1 molecules and uses are disclosed.

Estrogen receptor mutations and uses thereof

Methods of treating a head and neck cancer are disclosed.

Human papilloma virus as predictor of cancer prognosis

Methods and compositions for treating cancer such as melanomas are disclosed.

Methods of treating cancer

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

Methods of treating head and neck cancer

Growing community of inventors

Somerville, MA, United States of America

Garrett Michael Frampton